Mutual of America Capital Management LLC Has $5.04 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mutual of America Capital Management LLC decreased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,396 shares of the medical equipment provider’s stock after selling 1,540 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Zimmer Biomet were worth $5,035,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in Zimmer Biomet by 21.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,295 shares of the medical equipment provider’s stock valued at $2,835,000 after acquiring an additional 4,141 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Zimmer Biomet by 6.4% during the fourth quarter. Coldstream Capital Management Inc. now owns 2,842 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 170 shares during the period. D.A. Davidson & CO. increased its position in Zimmer Biomet by 18.9% during the fourth quarter. D.A. Davidson & CO. now owns 12,465 shares of the medical equipment provider’s stock worth $1,517,000 after buying an additional 1,984 shares during the last quarter. Corient Private Wealth LLC raised its stake in Zimmer Biomet by 5.3% in the fourth quarter. Corient Private Wealth LLC now owns 64,508 shares of the medical equipment provider’s stock valued at $7,851,000 after buying an additional 3,230 shares during the period. Finally, CreativeOne Wealth LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $209,000. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research analyst reports. Canaccord Genuity Group dropped their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. TD Cowen lowered their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Citigroup reduced their price objective on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Finally, Oppenheimer lowered their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $106.42 on Friday. The firm’s 50 day simple moving average is $109.83 and its 200 day simple moving average is $115.46. The firm has a market capitalization of $21.89 billion, a price-to-earnings ratio of 23.03, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter last year, the company posted $1.82 EPS. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. Zimmer Biomet’s payout ratio is currently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.